AC Immune SA (NASDAQ:ACIU) Short Interest Up 32.0% in July

AC Immune SA (NASDAQ:ACIU) was the target of a significant increase in short interest in July. As of July 15th, there was short interest totalling 964,900 shares, an increase of 32.0% from the June 30th total of 731,100 shares. Approximately 1.7% of the shares of the stock are sold short. Based on an average daily volume of 830,800 shares, the short-interest ratio is currently 1.2 days.

Hedge Funds Weigh In On AC Immune

A number of institutional investors and hedge funds have recently bought and sold shares of ACIU. Assenagon Asset Management S.A. grew its holdings in shares of AC Immune by 294.7% during the second quarter. Assenagon Asset Management S.A. now owns 439,730 shares of the company’s stock worth $1,755,000 after purchasing an additional 328,312 shares during the last quarter. Silverberg Bernstein Capital Management LLC acquired a new stake in AC Immune during the 2nd quarter worth approximately $40,000. Redmile Group LLC grew its holdings in AC Immune by 0.4% during the 1st quarter. Redmile Group LLC now owns 2,007,031 shares of the company’s stock worth $5,941,000 after acquiring an additional 7,031 shares during the last quarter. Lazard Asset Management LLC acquired a new position in AC Immune in the 1st quarter valued at approximately $30,000. Finally, BNP Paribas Financial Markets raised its stake in shares of AC Immune by 315.6% during the first quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock valued at $33,000 after acquiring an additional 8,423 shares during the last quarter. Institutional investors and hedge funds own 51.36% of the company’s stock.

AC Immune Price Performance

Shares of NASDAQ:ACIU opened at $3.91 on Monday. AC Immune has a one year low of $2.20 and a one year high of $5.14. The company has a market cap of $386.70 million, a price-to-earnings ratio of -5.67 and a beta of 1.27. The firm has a 50 day simple moving average of $3.94 and a 200 day simple moving average of $3.44.

AC Immune (NASDAQ:ACIU) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.06). As a group, analysts expect that AC Immune will post -0.2 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. BTIG Research began coverage on AC Immune in a report on Friday, May 31st. They issued a “buy” rating and a $8.00 target price on the stock. StockNews.com upgraded AC Immune from a “sell” rating to a “hold” rating in a research report on Wednesday, May 8th.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.